Healthcare Contract Manufacturing Market Share Analysis Report, 2023-2032
The global healthcare contract manufacturing market size was exhibited at USD 233.55 billion in 2022 and is projected to hit around USD 589.45 billion by 2032, growing at a CAGR of 9.7% during the forecast period 2023 to 2032.
Key Pointers:
Healthcare Contract Manufacturing Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 256.21 Billion |
|
Market Size by 2032 |
USD 589.45 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 9.7% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Type, end-use |
|
Regional scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key companies profiled |
Nordson Corporation; Integer Holdings Corporation; Jabil Inc.; Viant Technology LLC; FLEX LTD.; Celestica Inc.; Sanmina Corporation; Plexus Corp.; Phillips-Medisize; West Pharmaceutical Services, Inc.; Synecco; Catalent, Inc.; Thermo Fisher Scientific Inc.; Recipharm; Boehringer Ingelheim International GmbH; Lonza; Samsung Biologics; WuXi AppTec; FUJIFILM Diosynth Biotechnologies; Cambrex Corporation |
The increase in offshoring, especially in emerging countries, and the changing regulatory landscape, are the prominent trends currently present in the market. Pharmaceutical and medical device companies are outsourcing low-end services to third parties (CMOs) to reduce the overall cost of production and speed up the time to market of products. This trend is expected to contribute to the growth of the contract manufacturing market in the foreseeable future. COVID-19 brought in unparalleled demand for diagnostic tests, Personal Protective Equipment (PPE), ventilators, and other critical medical supplies. COVID-19 has had a major impact on the supply-demand gap, with a 1,000 to 2,000-fold increase for PPE products, raw material shortages increased by over 10% thereby pushing the by more than 100% in 2020.
The COVID-19 pandemic has forced many pharmaceutical and medical device companies to increase the manufacturing of drugs and medical devices needed by infected patients worldwide. The U.S. FDA has observed that over 60% of FDA-regulated products imported from China are medical devices, making U.S. medical device industry highly dependent on China’s supply chain. Medical device manufacturers are facing severe supply bottlenecks, which will ultimately reduce the company’s scope of revenue generation.
The presence of end-to-end service providers that are engaged in providing value-added services for an integrated or risk-sharing business model is expected to boost the market growth. Pharmaceutical and medical device companies are outsourcing manufacturing activities to CMOs to reduce their manufacturing footprint. It allows manufacturers to be more dynamic and cost-effective in their manufacturing process.
In addition, factors such as the increasing prevalence of noninvasive surgical procedures are driving the demand for pharmaceutical drugs and medical devices. To meet such increased demand, OEMs are outsourcing the manufacturing of non-core manufacturing activities as it assists them in reducing labor costs, freeing up capital, increasing worker productivity, and improving manufacturing lead times. For many large, medium and small pharma firms, outsourcing turns out to be an economic option, as fixed costs for manufacturing biologics products account for around 60–70% of the Cost of goods sold (COGS) and cannot be avoided even during idle conditions.
Therefore, the use of multi-product facilities to produce biologics has been proven economically efficient and safe as there is negligible to no risk with respect to product carryover, thereby supporting market growth. Since the medical device industry is highly regulated, making rapid changes in the supply chain may not be manageable. Medical device manufacturers distributing products in the U.S. are not required to report actual or potential supply chain shortages to the FDA. Despite this, the FDA is actively addressing potential shortages in the medical device supply chain. Some of the products facing shortage are aluminum products, integrated circuits, lithium-ion batteries, and special components, including pneumatic fittings, black body radiation source, & platinum.
This has created an unprecedented demand for the manufacturing of active pharmaceutical ingredients (APIs), finished doses, and medical devices in order to maintain supply. According to Medical Product Outsourcing, manufacturers expect outsourcing to yield cost savings and faster time to market. According to various reputed tabloids, companies are expected to outsource more work, based on a 2020 Global Managed Services Report. This report has performed a survey with 1,250 executives across 29 countries, which stated that 45% of organizations will outsource more in the coming years. However, the limited production capacity of CMOs may pose a major challenge restraining the market growth.
Some of the prominent players in the Healthcare Contract Manufacturing Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Healthcare Contract Manufacturing market.
By Type
By End use
By Region
Chapter 1. Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Type
1.1.2 Regional Scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Nova one advisor Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective - 1:
1.10.2 Objective - 2:
1.10.3 Objective - 3:
1.10.4 Objective - 4:
Chapter 2. Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3. Healthcare Contract Manufacturing Market: Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Ancillary market outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Industry Value Chain Analysis
3.3.1 Pharmaceutical contract manufacturing
3.3.2 Medical device contract manufacturing
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Implementation of international standards by contract manufacturers
3.4.1.2 Drug shortage driving the demand for pharmaceutical development
3.4.1.3 Commercial success of biologics for clinical use
3.4.2 Market Restraint Analysis
3.4.2.1 Regulatory and legal compliance
3.4.2.2 Threat of information loss
3.4.3 Industry Challenges
3.4.3.1 Managing relationships
3.5 Contract Manufacturing Market Analysis Tools
3.5.1 Porter’s Five Forces Analysis
3.5.2 PESTEL Analysis
3.5.3 Major Deals & Strategic Alliances Analysis
3.5.3.1 Mergers and acquisitions
3.5.3.2 Geographic expansion
3.5.3.3 Partnership
3.6 Impact of Covid-19 on Healthcare Contract Manufacturing Market
Chapter 4. Healthcare Contract Manufacturing Market: Type Segment Analysis
4.1 Healthcare Contract Manufacturing: Market Share Analysis, 2023 & 2032
4.2 Medical Device
4.2.1 Medical device market, 2020 - 2032
4.2.2 Service
4.2.2.1 Accessories manufacturing
4.2.2.1.1 Accessories manufacturing market, 2020 - 2032
4.2.2.2 Assembly manufacturing
4.2.2.2.1 Assembly manufacturing market, 2020 - 2032
4.2.2.3 Component manufacturing
4.2.2.3.1 Component manufacturing market, 2020 - 2032
4.2.2.4 Device manufacturing
4.2.2.4.1 Device manufacturing market, 2020 - 2032
4.2.3 Therapeutic area
4.2.3.1 Cardiology
4.2.3.1.1 Cardiology market, 2020 - 2032
4.2.3.2 Diagnostic imaging
4.2.3.2.1 Diagnostic imaging market, 2020 - 2032
4.2.3.3 Orthopedic
4.2.3.3.1 Orthopedic market, 2020 - 2032
4.2.3.4 IVD
4.2.3.4.1 IVD market, 2020 - 2032
4.2.3.5 Ophthalmic
4.2.3.5.1 Ophthalmic market, 2020 - 2032
4.2.3.6 General & plastic surgery
4.2.3.6.1 General & plastic surgery market, 2020 - 2032
4.2.3.7 Drug delivery
4.2.3.7.1 Drug delivery market, 2020 - 2032
4.2.3.8 Dental
4.2.3.8.1 Dental market, 2020 - 2032
4.2.3.9 Endoscopy
4.2.3.9.1 Endoscopy market, 2020 - 2032
4.2.3.10 Diabetes care
4.2.3.10.1 Diabetes care market, 2020 - 2032
4.2.3.11 Others
4.2.3.11.1 Others market, 2020 - 2032
4.3 Pharmaceutical
4.3.1 Pharmaceutical market, 2020 - 2032
4.3.2 Service
4.3.2.1 API/bulk drugs
4.3.2.1.1 API/bulk drugs market, 2020 - 2032
4.3.2.2 Advanced drug delivery formulations
4.3.2.2.1 Advanced drug delivery formulations market, 2020 - 2032
4.3.2.3 Packaging
4.3.2.3.1 Packaging market, 2020 - 2032
4.3.2.4 Finished dose formulations
4.3.2.4.1 Finished dose formulations market, 2020 - 2032
4.3.2.4.2 Solid
4.3.2.4.2.1 Solid market, 2020 - 2032
4.3.2.4.3 Liquid
4.3.2.4.3.1 Liquid market, 2020 - 2032
4.3.2.4.4 Semisolid formulations
4.3.2.4.4.1 Semisolid formulations market, 2020 - 2032
Chapter 5. Healthcare Contract Manufacturing Market: Type Segment Analysis
5.1 Healthcare Contract Manufacturing: Market Share Analysis, 2023 & 2032
5.2 Medical Device Companies
5.2.1 Medical device companies market, 2020 - 2032
5.3 Pharmaceutical Companies
5.3.1 Pharmaceutical companies market, 2020 - 2032
5.4 Pharmaceutical Companies
5.4.1 Biopharmaceutical companies market, 2020 - 2032
Chapter 6. Healthcare Contract Manufacturing Market: Regional Analysis
6.1 Healthcare Contract Manufacturing: Regional Market Share
6.2 Healthcare Contract Manufacturing: Market Share Analysis, 2023 & 2032
6.3 North America
6.3.1 North America Healthcare Contract Manufacturing market, 2020 - 2032
6.3.2 U.S.
6.3.2.1 U.S. healthcare contract manufacturing market, 2020 - 2032
6.3.3 Canada
6.3.3.1 Canada healthcare contract manufacturing market, 2020 - 2032
6.4 Europe
6.4.1 Europe Healthcare Contract Manufacturing market, 2020 - 2032
6.4.2 U.K.
6.4.2.1 U.K. healthcare contract manufacturing market, 2020 - 2032
6.4.3 Germany
6.4.3.1 Germany healthcare contract manufacturing market, 2020 - 2032
6.4.4 France
6.4.4.1 France healthcare contract manufacturing market, 2020 - 2032
6.4.5 Italy
6.4.5.1 Italy healthcare contract manufacturing market, 2020 - 2032
6.4.6 Spain
6.4.6.1 Spain healthcare contract manufacturing market, 2020 - 2032
6.4.7 Russia
6.4.7.1 Russia healthcare contract manufacturing market, 2020 - 2032
6.4.8 Belgium
6.4.8.1 Belgium healthcare contract manufacturing market, 2020 - 2032
6.4.9 Netherlands
6.4.9.1 Netherlands healthcare contract manufacturing market, 2020 - 2032
6.4.10 Switzerland
6.4.10.1 Switzerland healthcare contract manufacturing market, 2020 - 2032
6.4.11 Sweden
6.4.11.1 Sweden healthcare contract manufacturing market, 2020 - 2032
6.5 Asia Pacific
6.5.1 Asia Pacific Healthcare Contract Manufacturing market, 2020 - 2032
6.5.2 India
6.5.2.1 India healthcare contract manufacturing market, 2020 - 2032
6.5.3 Japan
6.5.3.1 Japan healthcare contract manufacturing market, 2020 - 2032
6.5.4 China
6.5.4.1 China healthcare contract manufacturing market, 2020 - 2032
6.5.5 South Korea
6.5.5.1 South Korea healthcare contract manufacturing market, 2020 - 2032
6.5.6 Australia
6.5.6.1 Australia healthcare contract manufacturing market, 2020 - 2032
6.5.7 Indonesia
6.5.7.1 Indonesia healthcare contract manufacturing market, 2020 - 2032
6.5.8 Malaysia
6.5.8.1 Malaysia healthcare contract manufacturing market, 2020 - 2032
6.5.9 Singapore
6.5.9.1 Singapore healthcare contract manufacturing market, 2020 - 2032
6.5.10 Thailand
6.5.10.1 Thailand healthcare contract manufacturing market, 2020 - 2032
6.5.11 Taiwan
6.5.11.1 Taiwan healthcare contract manufacturing market, 2020 - 2032
6.6 Latin America
6.6.1 Latin America Healthcare Contract Manufacturing market, 2020 - 2032
6.6.2 Brazil
6.6.2.1 Brazil healthcare contract manufacturing market, 2020 - 2032
6.6.3 Mexico
6.6.3.1 Mexico healthcare contract manufacturing market, 2020 - 2032
6.6.4 Argentina
6.6.4.1 Argentina healthcare contract manufacturing market, 2020 - 2032
6.6.5 Colombia
6.6.5.1 Colombia healthcare contract manufacturing market, 2020 - 2032
6.6.6 Chile
6.6.6.1 Chile healthcare contract manufacturing market, 2020 - 2032
6.7 MEA
6.7.1 MEA Healthcare Contract Manufacturing market, 2020 - 2032
6.7.2 South Africa
6.7.2.1 South Africa healthcare contract manufacturing market, 2020 - 2032
6.7.3 Saudi Arabia
6.7.3.1 Saudi Arabia healthcare contract manufacturing market, 2020 - 2032
6.7.4 UAE
6.7.4.1 UAE healthcare contract manufacturing market, 2020 - 2032
6.7.5 Israel
6.7.5.1 Israel healthcare contract manufacturing market, 2020 - 2032
6.7.6 Egypt
6.7.6.1 Egypt healthcare contract manufacturing market, 2020 - 2032
Chapter 7. Company Profiles
7.1 Company Profiles
7.1.1 NORDSON CORPORATION
7.1.1.1 Company overview
7.1.1.2 Financial performance
7.1.1.3 Service benchmarking
7.1.1.4 Strategic initiatives
7.1.2 INTEGER HOLDINGS CORPORATION
7.1.2.1 Company overview
7.1.2.2 Financial performance
7.1.2.3 Service benchmarking
7.1.2.4 Strategic initiatives
7.1.3 JABIL INC.
7.1.3.1 Company overview
7.1.3.2 Financial performance
7.1.3.3 Service benchmarking
7.1.3.4 Strategic initiatives
7.1.4 VIANT
7.1.4.1 Company overview
7.1.4.2 Service benchmarking
7.1.4.3 Strategic initiatives
7.1.5 FLEX LTD.
7.1.5.1 Company overview
7.1.5.2 Financial performance
7.1.5.3 Service benchmarking
7.1.5.4 Strategic initiatives
7.1.6 CELESTICA INC.
7.1.6.1 Company overview
7.1.6.2 Financial performance
7.1.6.3 Service benchmarking
7.1.6.4 Strategic initiatives
7.1.7 SANMINA CORPORATION
7.1.7.1 Company overview
7.1.7.2 Financial performance
7.1.7.3 Service benchmarking
7.1.7.4 Strategic initiatives
7.1.8 PLEXUS CORP.
7.1.8.1 Company overview
7.1.8.2 Financial performance
7.1.8.3 Service benchmarking
7.1.8.4 Strategic initiatives
7.1.9 PHILLIPS MEDISIZE
7.1.9.1 Company overview
7.1.9.2 Service benchmarking
7.1.9.3 Strategic initiatives
7.1.10 WEST PHARMACEUTICAL SERVICES, INC.
7.1.10.1 Company overview
7.1.10.2 Financial performance
7.1.10.3 Service benchmarking
7.1.10.4 Strategic initiatives
7.1.11 SYNECCO
7.1.11.1 Company overview
7.1.11.2 Service benchmarking
7.1.12 CATALENT, INC
7.1.12.1 Company overview
7.1.12.2 Financial performance
7.1.12.3 Service benchmarking
7.1.12.4 Strategic initiatives
7.1.13 THERMO FISHER SCIENTIFIC INC.
7.1.13.1 Company overview
7.1.13.2 Financial performance
7.1.13.3 Service benchmarking
7.1.13.4 Strategic initiatives
7.1.14 RECIPHARM
7.1.14.1 Company overview
7.1.14.2 Financial performance
7.1.14.3 Service benchmarking
7.1.14.4 Strategic initiatives
7.1.15 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
7.1.15.1 Company overview
7.1.15.2 Financial performance
7.1.15.3 Service benchmarking
7.1.15.4 Strategic initiatives
7.1.16 LONZA
7.1.16.1 Company overview
7.1.16.2 Financial performance
7.1.16.3 Service benchmarking
7.1.16.4 Strategic initiatives
7.1.17 SAMSUNG BIOLOGICS
7.1.17.1 Company overview
7.1.17.2 Financial performance
7.1.17.3 Service benchmarking
7.1.17.4 Strategic initiatives
7.1.18 WUXI APPTECH
7.1.18.1 Company overview
7.1.18.2 Financial performance
7.1.18.3 Service benchmarking
7.1.18.4 Strategic initiatives
7.1.19 FUJIFILM DIOSYNTH BIOTECHNOLOGIES
7.1.19.1 Company overview
7.1.19.2 Financial performance
7.1.19.3 Service benchmarking
7.1.19.4 Strategic initiatives
7.1.20 CAMBREX CORPORATION
7.1.20.1 Company overview
7.1.20.2 Financial performance
7.1.20.3 Service benchmarking
7.1.20.4 Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers